nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—HTR2C—Sorafenib—kidney cancer	0.0857	0.197	CbGbCtD
Duloxetine—CYP2D6—Temsirolimus—kidney cancer	0.0843	0.193	CbGbCtD
Duloxetine—CYP1A2—Pazopanib—kidney cancer	0.0538	0.123	CbGbCtD
Duloxetine—CYP2D6—Pazopanib—kidney cancer	0.0443	0.102	CbGbCtD
Duloxetine—CYP1A2—Erlotinib—kidney cancer	0.0384	0.088	CbGbCtD
Duloxetine—CYP2D6—Erlotinib—kidney cancer	0.0316	0.0725	CbGbCtD
Duloxetine—CYP1A2—Sorafenib—kidney cancer	0.0312	0.0716	CbGbCtD
Duloxetine—CYP2D6—Sorafenib—kidney cancer	0.0257	0.059	CbGbCtD
Duloxetine—CYP2D6—Vinblastine—kidney cancer	0.0254	0.0582	CbGbCtD
Duloxetine—CYP2D6—Doxorubicin—kidney cancer	0.0156	0.0358	CbGbCtD
Duloxetine—CYP1A2—urine—kidney cancer	0.00167	0.152	CbGeAlD
Duloxetine—NPY1R—renal system—kidney cancer	0.00157	0.143	CbGeAlD
Duloxetine—NPY1R—cortex of kidney—kidney cancer	0.00148	0.134	CbGeAlD
Duloxetine—NPY1R—gonad—kidney cancer	0.00141	0.128	CbGeAlD
Duloxetine—HTR2A—urine—kidney cancer	0.00131	0.119	CbGeAlD
Duloxetine—CYP2D6—urine—kidney cancer	0.00119	0.108	CbGeAlD
Duloxetine—SLC6A2—gonad—kidney cancer	0.000477	0.0434	CbGeAlD
Duloxetine—CYP1A2—renal system—kidney cancer	0.000409	0.0372	CbGeAlD
Duloxetine—HTR2A—renal system—kidney cancer	0.00032	0.0291	CbGeAlD
Duloxetine—HTR2A—kidney—kidney cancer	0.000309	0.0281	CbGeAlD
Duloxetine—CYP2D6—renal system—kidney cancer	0.000291	0.0265	CbGeAlD
Duloxetine—HTR2A—gonad—kidney cancer	0.000287	0.0261	CbGeAlD
Duloxetine—CYP2D6—kidney—kidney cancer	0.000282	0.0256	CbGeAlD
Duloxetine—Protriptyline—ABCB1—kidney cancer	0.000254	0.347	CrCbGaD
Duloxetine—Propranolol—CYP1A1—kidney cancer	0.000199	0.272	CrCbGaD
Duloxetine—Fluoxetine—ABCB1—kidney cancer	0.000173	0.237	CrCbGaD
Duloxetine—Mental disorder—Capecitabine—kidney cancer	0.000142	0.000286	CcSEcCtD
Duloxetine—Asthenia—Dactinomycin—kidney cancer	0.000141	0.000286	CcSEcCtD
Duloxetine—Confusional state—Paclitaxel—kidney cancer	0.000141	0.000285	CcSEcCtD
Duloxetine—Blood creatinine increased—Doxorubicin—kidney cancer	0.000141	0.000285	CcSEcCtD
Duloxetine—Malnutrition—Capecitabine—kidney cancer	0.000141	0.000284	CcSEcCtD
Duloxetine—Erythema—Capecitabine—kidney cancer	0.000141	0.000284	CcSEcCtD
Duloxetine—Dehydration—Doxorubicin—kidney cancer	0.00014	0.000283	CcSEcCtD
Duloxetine—Oedema—Paclitaxel—kidney cancer	0.00014	0.000283	CcSEcCtD
Duloxetine—Anaphylactic shock—Paclitaxel—kidney cancer	0.00014	0.000283	CcSEcCtD
Duloxetine—Abdominal pain—Vincristine—kidney cancer	0.000139	0.000281	CcSEcCtD
Duloxetine—Body temperature increased—Vincristine—kidney cancer	0.000139	0.000281	CcSEcCtD
Duloxetine—Liver function test abnormal—Doxorubicin—kidney cancer	0.000139	0.000281	CcSEcCtD
Duloxetine—Infection—Paclitaxel—kidney cancer	0.000139	0.000281	CcSEcCtD
Duloxetine—Flatulence—Capecitabine—kidney cancer	0.000139	0.00028	CcSEcCtD
Duloxetine—Dysgeusia—Capecitabine—kidney cancer	0.000138	0.000278	CcSEcCtD
Duloxetine—Dizziness—Sunitinib—kidney cancer	0.000138	0.000278	CcSEcCtD
Duloxetine—Feeling abnormal—Gemcitabine—kidney cancer	0.000138	0.000278	CcSEcCtD
Duloxetine—Shock—Paclitaxel—kidney cancer	0.000138	0.000278	CcSEcCtD
Duloxetine—Vomiting—Sorafenib—kidney cancer	0.000138	0.000278	CcSEcCtD
Duloxetine—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000137	0.000278	CcSEcCtD
Duloxetine—Abdominal pain upper—Doxorubicin—kidney cancer	0.000137	0.000278	CcSEcCtD
Duloxetine—Nervous system disorder—Paclitaxel—kidney cancer	0.000137	0.000277	CcSEcCtD
Duloxetine—Thrombocytopenia—Paclitaxel—kidney cancer	0.000137	0.000277	CcSEcCtD
Duloxetine—Tachycardia—Paclitaxel—kidney cancer	0.000136	0.000276	CcSEcCtD
Duloxetine—Rash—Sorafenib—kidney cancer	0.000136	0.000276	CcSEcCtD
Duloxetine—Dermatitis—Sorafenib—kidney cancer	0.000136	0.000275	CcSEcCtD
Duloxetine—Back pain—Capecitabine—kidney cancer	0.000136	0.000275	CcSEcCtD
Duloxetine—Breast disorder—Doxorubicin—kidney cancer	0.000136	0.000275	CcSEcCtD
Duloxetine—Skin disorder—Paclitaxel—kidney cancer	0.000136	0.000275	CcSEcCtD
Duloxetine—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.000136	0.000274	CcSEcCtD
Duloxetine—Headache—Sorafenib—kidney cancer	0.000136	0.000274	CcSEcCtD
Duloxetine—Muscle spasms—Capecitabine—kidney cancer	0.000135	0.000273	CcSEcCtD
Duloxetine—Hyperhidrosis—Paclitaxel—kidney cancer	0.000135	0.000273	CcSEcCtD
Duloxetine—Diarrhoea—Dactinomycin—kidney cancer	0.000135	0.000273	CcSEcCtD
Duloxetine—Nasopharyngitis—Doxorubicin—kidney cancer	0.000135	0.000272	CcSEcCtD
Duloxetine—Anorexia—Paclitaxel—kidney cancer	0.000133	0.000269	CcSEcCtD
Duloxetine—Gastritis—Doxorubicin—kidney cancer	0.000133	0.000269	CcSEcCtD
Duloxetine—Muscular weakness—Doxorubicin—kidney cancer	0.000133	0.000268	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.000133	0.000268	CcSEcCtD
Duloxetine—Vision blurred—Capecitabine—kidney cancer	0.000133	0.000268	CcSEcCtD
Duloxetine—Vomiting—Sunitinib—kidney cancer	0.000132	0.000268	CcSEcCtD
Duloxetine—Body temperature increased—Gemcitabine—kidney cancer	0.000132	0.000267	CcSEcCtD
Duloxetine—Tremor—Capecitabine—kidney cancer	0.000132	0.000266	CcSEcCtD
Duloxetine—Rash—Sunitinib—kidney cancer	0.000131	0.000265	CcSEcCtD
Duloxetine—Dermatitis—Sunitinib—kidney cancer	0.000131	0.000265	CcSEcCtD
Duloxetine—Ill-defined disorder—Capecitabine—kidney cancer	0.00013	0.000264	CcSEcCtD
Duloxetine—Headache—Sunitinib—kidney cancer	0.00013	0.000264	CcSEcCtD
Duloxetine—Dysphagia—Doxorubicin—kidney cancer	0.00013	0.000263	CcSEcCtD
Duloxetine—Influenza—Doxorubicin—kidney cancer	0.00013	0.000263	CcSEcCtD
Duloxetine—Anaemia—Capecitabine—kidney cancer	0.00013	0.000263	CcSEcCtD
Duloxetine—Hypersensitivity—Vincristine—kidney cancer	0.00013	0.000262	CcSEcCtD
Duloxetine—Nausea—Sorafenib—kidney cancer	0.000128	0.00026	CcSEcCtD
Duloxetine—Pancreatitis—Doxorubicin—kidney cancer	0.000128	0.000258	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000127	0.000258	CcSEcCtD
Duloxetine—Malaise—Capecitabine—kidney cancer	0.000127	0.000256	CcSEcCtD
Duloxetine—Insomnia—Paclitaxel—kidney cancer	0.000126	0.000256	CcSEcCtD
Duloxetine—Vertigo—Capecitabine—kidney cancer	0.000126	0.000255	CcSEcCtD
Duloxetine—Asthenia—Vincristine—kidney cancer	0.000126	0.000255	CcSEcCtD
Duloxetine—Syncope—Capecitabine—kidney cancer	0.000126	0.000255	CcSEcCtD
Duloxetine—Leukopenia—Capecitabine—kidney cancer	0.000126	0.000254	CcSEcCtD
Duloxetine—Paraesthesia—Paclitaxel—kidney cancer	0.000126	0.000254	CcSEcCtD
Duloxetine—Vomiting—Dactinomycin—kidney cancer	0.000125	0.000253	CcSEcCtD
Duloxetine—Somnolence—Paclitaxel—kidney cancer	0.000124	0.000251	CcSEcCtD
Duloxetine—Palpitations—Capecitabine—kidney cancer	0.000124	0.000251	CcSEcCtD
Duloxetine—Rash—Dactinomycin—kidney cancer	0.000124	0.000251	CcSEcCtD
Duloxetine—Nausea—Sunitinib—kidney cancer	0.000124	0.00025	CcSEcCtD
Duloxetine—Loss of consciousness—Capecitabine—kidney cancer	0.000124	0.00025	CcSEcCtD
Duloxetine—Dyspepsia—Paclitaxel—kidney cancer	0.000123	0.000249	CcSEcCtD
Duloxetine—Cough—Capecitabine—kidney cancer	0.000123	0.000248	CcSEcCtD
Duloxetine—Dysuria—Doxorubicin—kidney cancer	0.000122	0.000246	CcSEcCtD
Duloxetine—Decreased appetite—Paclitaxel—kidney cancer	0.000122	0.000246	CcSEcCtD
Duloxetine—Hypertension—Capecitabine—kidney cancer	0.000121	0.000245	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000121	0.000244	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000121	0.000244	CcSEcCtD
Duloxetine—Fatigue—Paclitaxel—kidney cancer	0.000121	0.000244	CcSEcCtD
Duloxetine—Diarrhoea—Vincristine—kidney cancer	0.00012	0.000243	CcSEcCtD
Duloxetine—Pollakiuria—Doxorubicin—kidney cancer	0.00012	0.000243	CcSEcCtD
Duloxetine—Asthenia—Gemcitabine—kidney cancer	0.00012	0.000242	CcSEcCtD
Duloxetine—Myalgia—Capecitabine—kidney cancer	0.00012	0.000242	CcSEcCtD
Duloxetine—Chest pain—Capecitabine—kidney cancer	0.00012	0.000242	CcSEcCtD
Duloxetine—Arthralgia—Capecitabine—kidney cancer	0.00012	0.000242	CcSEcCtD
Duloxetine—Constipation—Paclitaxel—kidney cancer	0.00012	0.000242	CcSEcCtD
Duloxetine—Pain—Paclitaxel—kidney cancer	0.00012	0.000242	CcSEcCtD
Duloxetine—Anxiety—Capecitabine—kidney cancer	0.000119	0.000241	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000119	0.00024	CcSEcCtD
Duloxetine—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000119	0.00024	CcSEcCtD
Duloxetine—Weight increased—Doxorubicin—kidney cancer	0.000118	0.000239	CcSEcCtD
Duloxetine—Discomfort—Capecitabine—kidney cancer	0.000118	0.000239	CcSEcCtD
Duloxetine—Pruritus—Gemcitabine—kidney cancer	0.000118	0.000239	CcSEcCtD
Duloxetine—Weight decreased—Doxorubicin—kidney cancer	0.000118	0.000238	CcSEcCtD
Duloxetine—Hyperglycaemia—Doxorubicin—kidney cancer	0.000117	0.000237	CcSEcCtD
Duloxetine—Dry mouth—Capecitabine—kidney cancer	0.000117	0.000237	CcSEcCtD
Duloxetine—Nausea—Dactinomycin—kidney cancer	0.000117	0.000237	CcSEcCtD
Duloxetine—Dizziness—Vincristine—kidney cancer	0.000116	0.000235	CcSEcCtD
Duloxetine—Infestation NOS—Doxorubicin—kidney cancer	0.000116	0.000234	CcSEcCtD
Duloxetine—Infestation—Doxorubicin—kidney cancer	0.000116	0.000234	CcSEcCtD
Duloxetine—Confusional state—Capecitabine—kidney cancer	0.000116	0.000234	CcSEcCtD
Duloxetine—Feeling abnormal—Paclitaxel—kidney cancer	0.000115	0.000233	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000115	0.000232	CcSEcCtD
Duloxetine—Oedema—Capecitabine—kidney cancer	0.000115	0.000232	CcSEcCtD
Duloxetine—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000114	0.000231	CcSEcCtD
Duloxetine—Diarrhoea—Gemcitabine—kidney cancer	0.000114	0.000231	CcSEcCtD
Duloxetine—Renal failure—Doxorubicin—kidney cancer	0.000114	0.00023	CcSEcCtD
Duloxetine—Infection—Capecitabine—kidney cancer	0.000114	0.00023	CcSEcCtD
Duloxetine—Stomatitis—Doxorubicin—kidney cancer	0.000113	0.000229	CcSEcCtD
Duloxetine—Jaundice—Doxorubicin—kidney cancer	0.000113	0.000229	CcSEcCtD
Duloxetine—Shock—Capecitabine—kidney cancer	0.000113	0.000228	CcSEcCtD
Duloxetine—Conjunctivitis—Doxorubicin—kidney cancer	0.000113	0.000228	CcSEcCtD
Duloxetine—Urinary tract infection—Doxorubicin—kidney cancer	0.000113	0.000228	CcSEcCtD
Duloxetine—Nervous system disorder—Capecitabine—kidney cancer	0.000113	0.000227	CcSEcCtD
Duloxetine—Thrombocytopenia—Capecitabine—kidney cancer	0.000112	0.000227	CcSEcCtD
Duloxetine—Tachycardia—Capecitabine—kidney cancer	0.000112	0.000226	CcSEcCtD
Duloxetine—Vomiting—Vincristine—kidney cancer	0.000112	0.000226	CcSEcCtD
Duloxetine—Skin disorder—Capecitabine—kidney cancer	0.000111	0.000225	CcSEcCtD
Duloxetine—Urticaria—Paclitaxel—kidney cancer	0.000111	0.000225	CcSEcCtD
Duloxetine—Rash—Vincristine—kidney cancer	0.000111	0.000224	CcSEcCtD
Duloxetine—Hyperhidrosis—Capecitabine—kidney cancer	0.000111	0.000224	CcSEcCtD
Duloxetine—Dermatitis—Vincristine—kidney cancer	0.000111	0.000224	CcSEcCtD
Duloxetine—Abdominal pain—Paclitaxel—kidney cancer	0.000111	0.000223	CcSEcCtD
Duloxetine—Body temperature increased—Paclitaxel—kidney cancer	0.000111	0.000223	CcSEcCtD
Duloxetine—Headache—Vincristine—kidney cancer	0.00011	0.000223	CcSEcCtD
Duloxetine—Hepatobiliary disease—Doxorubicin—kidney cancer	0.00011	0.000222	CcSEcCtD
Duloxetine—Epistaxis—Doxorubicin—kidney cancer	0.000109	0.000221	CcSEcCtD
Duloxetine—Anorexia—Capecitabine—kidney cancer	0.000109	0.000221	CcSEcCtD
Duloxetine—Vomiting—Gemcitabine—kidney cancer	0.000106	0.000215	CcSEcCtD
Duloxetine—Propranolol—ABCB1—kidney cancer	0.000106	0.145	CrCbGaD
Duloxetine—Rash—Gemcitabine—kidney cancer	0.000105	0.000213	CcSEcCtD
Duloxetine—Dermatitis—Gemcitabine—kidney cancer	0.000105	0.000213	CcSEcCtD
Duloxetine—Haemoglobin—Doxorubicin—kidney cancer	0.000105	0.000212	CcSEcCtD
Duloxetine—Headache—Gemcitabine—kidney cancer	0.000105	0.000211	CcSEcCtD
Duloxetine—Nausea—Vincristine—kidney cancer	0.000105	0.000211	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000105	0.000211	CcSEcCtD
Duloxetine—Haemorrhage—Doxorubicin—kidney cancer	0.000104	0.00021	CcSEcCtD
Duloxetine—Hepatitis—Doxorubicin—kidney cancer	0.000104	0.00021	CcSEcCtD
Duloxetine—Insomnia—Capecitabine—kidney cancer	0.000104	0.00021	CcSEcCtD
Duloxetine—Hypoaesthesia—Doxorubicin—kidney cancer	0.000104	0.000209	CcSEcCtD
Duloxetine—Pharyngitis—Doxorubicin—kidney cancer	0.000103	0.000209	CcSEcCtD
Duloxetine—Paraesthesia—Capecitabine—kidney cancer	0.000103	0.000208	CcSEcCtD
Duloxetine—Hypersensitivity—Paclitaxel—kidney cancer	0.000103	0.000208	CcSEcCtD
Duloxetine—Urinary tract disorder—Doxorubicin—kidney cancer	0.000103	0.000208	CcSEcCtD
Duloxetine—Oedema peripheral—Doxorubicin—kidney cancer	0.000103	0.000207	CcSEcCtD
Duloxetine—Connective tissue disorder—Doxorubicin—kidney cancer	0.000102	0.000207	CcSEcCtD
Duloxetine—Urethral disorder—Doxorubicin—kidney cancer	0.000102	0.000206	CcSEcCtD
Duloxetine—Dyspepsia—Capecitabine—kidney cancer	0.000101	0.000204	CcSEcCtD
Duloxetine—Visual impairment—Doxorubicin—kidney cancer	0.0001	0.000203	CcSEcCtD
Duloxetine—Asthenia—Paclitaxel—kidney cancer	0.0001	0.000203	CcSEcCtD
Duloxetine—Decreased appetite—Capecitabine—kidney cancer	9.98e-05	0.000202	CcSEcCtD
Duloxetine—Nausea—Gemcitabine—kidney cancer	9.92e-05	0.000201	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Capecitabine—kidney cancer	9.91e-05	0.0002	CcSEcCtD
Duloxetine—Fatigue—Capecitabine—kidney cancer	9.89e-05	0.0002	CcSEcCtD
Duloxetine—Pruritus—Paclitaxel—kidney cancer	9.89e-05	0.0002	CcSEcCtD
Duloxetine—Erythema multiforme—Doxorubicin—kidney cancer	9.84e-05	0.000199	CcSEcCtD
Duloxetine—Constipation—Capecitabine—kidney cancer	9.81e-05	0.000198	CcSEcCtD
Duloxetine—Pain—Capecitabine—kidney cancer	9.81e-05	0.000198	CcSEcCtD
Duloxetine—Eye disorder—Doxorubicin—kidney cancer	9.73e-05	0.000197	CcSEcCtD
Duloxetine—Tinnitus—Doxorubicin—kidney cancer	9.71e-05	0.000196	CcSEcCtD
Duloxetine—Cardiac disorder—Doxorubicin—kidney cancer	9.66e-05	0.000195	CcSEcCtD
Duloxetine—Flushing—Doxorubicin—kidney cancer	9.66e-05	0.000195	CcSEcCtD
Duloxetine—Diarrhoea—Paclitaxel—kidney cancer	9.57e-05	0.000193	CcSEcCtD
Duloxetine—Feeling abnormal—Capecitabine—kidney cancer	9.46e-05	0.000191	CcSEcCtD
Duloxetine—Angiopathy—Doxorubicin—kidney cancer	9.45e-05	0.000191	CcSEcCtD
Duloxetine—Immune system disorder—Doxorubicin—kidney cancer	9.4e-05	0.00019	CcSEcCtD
Duloxetine—Gastrointestinal pain—Capecitabine—kidney cancer	9.38e-05	0.00019	CcSEcCtD
Duloxetine—Mediastinal disorder—Doxorubicin—kidney cancer	9.38e-05	0.00019	CcSEcCtD
Duloxetine—Chills—Doxorubicin—kidney cancer	9.34e-05	0.000189	CcSEcCtD
Duloxetine—Arrhythmia—Doxorubicin—kidney cancer	9.3e-05	0.000188	CcSEcCtD
Duloxetine—Dizziness—Paclitaxel—kidney cancer	9.25e-05	0.000187	CcSEcCtD
Duloxetine—Alopecia—Doxorubicin—kidney cancer	9.2e-05	0.000186	CcSEcCtD
Duloxetine—Mental disorder—Doxorubicin—kidney cancer	9.12e-05	0.000184	CcSEcCtD
Duloxetine—Urticaria—Capecitabine—kidney cancer	9.12e-05	0.000184	CcSEcCtD
Duloxetine—Body temperature increased—Capecitabine—kidney cancer	9.07e-05	0.000183	CcSEcCtD
Duloxetine—Abdominal pain—Capecitabine—kidney cancer	9.07e-05	0.000183	CcSEcCtD
Duloxetine—Malnutrition—Doxorubicin—kidney cancer	9.06e-05	0.000183	CcSEcCtD
Duloxetine—Erythema—Doxorubicin—kidney cancer	9.06e-05	0.000183	CcSEcCtD
Duloxetine—Flatulence—Doxorubicin—kidney cancer	8.93e-05	0.000181	CcSEcCtD
Duloxetine—Tension—Doxorubicin—kidney cancer	8.89e-05	0.00018	CcSEcCtD
Duloxetine—Vomiting—Paclitaxel—kidney cancer	8.89e-05	0.00018	CcSEcCtD
Duloxetine—Dysgeusia—Doxorubicin—kidney cancer	8.88e-05	0.000179	CcSEcCtD
Duloxetine—Rash—Paclitaxel—kidney cancer	8.82e-05	0.000178	CcSEcCtD
Duloxetine—Dermatitis—Paclitaxel—kidney cancer	8.81e-05	0.000178	CcSEcCtD
Duloxetine—Nervousness—Doxorubicin—kidney cancer	8.8e-05	0.000178	CcSEcCtD
Duloxetine—Back pain—Doxorubicin—kidney cancer	8.77e-05	0.000177	CcSEcCtD
Duloxetine—Headache—Paclitaxel—kidney cancer	8.76e-05	0.000177	CcSEcCtD
Duloxetine—Muscle spasms—Doxorubicin—kidney cancer	8.71e-05	0.000176	CcSEcCtD
Duloxetine—Vision blurred—Doxorubicin—kidney cancer	8.54e-05	0.000173	CcSEcCtD
Duloxetine—Hypersensitivity—Capecitabine—kidney cancer	8.45e-05	0.000171	CcSEcCtD
Duloxetine—Ill-defined disorder—Doxorubicin—kidney cancer	8.41e-05	0.00017	CcSEcCtD
Duloxetine—Anaemia—Doxorubicin—kidney cancer	8.38e-05	0.000169	CcSEcCtD
Duloxetine—Agitation—Doxorubicin—kidney cancer	8.33e-05	0.000168	CcSEcCtD
Duloxetine—Nausea—Paclitaxel—kidney cancer	8.31e-05	0.000168	CcSEcCtD
Duloxetine—Asthenia—Capecitabine—kidney cancer	8.23e-05	0.000166	CcSEcCtD
Duloxetine—Malaise—Doxorubicin—kidney cancer	8.17e-05	0.000165	CcSEcCtD
Duloxetine—Vertigo—Doxorubicin—kidney cancer	8.14e-05	0.000165	CcSEcCtD
Duloxetine—Syncope—Doxorubicin—kidney cancer	8.13e-05	0.000164	CcSEcCtD
Duloxetine—Pruritus—Capecitabine—kidney cancer	8.12e-05	0.000164	CcSEcCtD
Duloxetine—Leukopenia—Doxorubicin—kidney cancer	8.11e-05	0.000164	CcSEcCtD
Duloxetine—Palpitations—Doxorubicin—kidney cancer	8.01e-05	0.000162	CcSEcCtD
Duloxetine—Loss of consciousness—Doxorubicin—kidney cancer	7.97e-05	0.000161	CcSEcCtD
Duloxetine—Cough—Doxorubicin—kidney cancer	7.91e-05	0.00016	CcSEcCtD
Duloxetine—Convulsion—Doxorubicin—kidney cancer	7.85e-05	0.000159	CcSEcCtD
Duloxetine—Diarrhoea—Capecitabine—kidney cancer	7.85e-05	0.000159	CcSEcCtD
Duloxetine—Hypertension—Doxorubicin—kidney cancer	7.83e-05	0.000158	CcSEcCtD
Duloxetine—Chest pain—Doxorubicin—kidney cancer	7.72e-05	0.000156	CcSEcCtD
Duloxetine—Arthralgia—Doxorubicin—kidney cancer	7.72e-05	0.000156	CcSEcCtD
Duloxetine—Myalgia—Doxorubicin—kidney cancer	7.72e-05	0.000156	CcSEcCtD
Duloxetine—Anxiety—Doxorubicin—kidney cancer	7.69e-05	0.000155	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	7.66e-05	0.000155	CcSEcCtD
Duloxetine—Discomfort—Doxorubicin—kidney cancer	7.62e-05	0.000154	CcSEcCtD
Duloxetine—Dizziness—Capecitabine—kidney cancer	7.59e-05	0.000153	CcSEcCtD
Duloxetine—Dry mouth—Doxorubicin—kidney cancer	7.55e-05	0.000153	CcSEcCtD
Duloxetine—Confusional state—Doxorubicin—kidney cancer	7.46e-05	0.000151	CcSEcCtD
Duloxetine—Oedema—Doxorubicin—kidney cancer	7.4e-05	0.00015	CcSEcCtD
Duloxetine—Anaphylactic shock—Doxorubicin—kidney cancer	7.4e-05	0.00015	CcSEcCtD
Duloxetine—Infection—Doxorubicin—kidney cancer	7.35e-05	0.000149	CcSEcCtD
Duloxetine—Vomiting—Capecitabine—kidney cancer	7.3e-05	0.000147	CcSEcCtD
Duloxetine—Shock—Doxorubicin—kidney cancer	7.28e-05	0.000147	CcSEcCtD
Duloxetine—Nervous system disorder—Doxorubicin—kidney cancer	7.25e-05	0.000147	CcSEcCtD
Duloxetine—Thrombocytopenia—Doxorubicin—kidney cancer	7.24e-05	0.000146	CcSEcCtD
Duloxetine—Rash—Capecitabine—kidney cancer	7.24e-05	0.000146	CcSEcCtD
Duloxetine—Dermatitis—Capecitabine—kidney cancer	7.23e-05	0.000146	CcSEcCtD
Duloxetine—Tachycardia—Doxorubicin—kidney cancer	7.22e-05	0.000146	CcSEcCtD
Duloxetine—Headache—Capecitabine—kidney cancer	7.19e-05	0.000145	CcSEcCtD
Duloxetine—Skin disorder—Doxorubicin—kidney cancer	7.19e-05	0.000145	CcSEcCtD
Duloxetine—Hyperhidrosis—Doxorubicin—kidney cancer	7.15e-05	0.000145	CcSEcCtD
Duloxetine—Anorexia—Doxorubicin—kidney cancer	7.05e-05	0.000143	CcSEcCtD
Duloxetine—Nausea—Capecitabine—kidney cancer	6.82e-05	0.000138	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	6.74e-05	0.000136	CcSEcCtD
Duloxetine—Insomnia—Doxorubicin—kidney cancer	6.69e-05	0.000135	CcSEcCtD
Duloxetine—Paraesthesia—Doxorubicin—kidney cancer	6.64e-05	0.000134	CcSEcCtD
Duloxetine—Somnolence—Doxorubicin—kidney cancer	6.58e-05	0.000133	CcSEcCtD
Duloxetine—Dyspepsia—Doxorubicin—kidney cancer	6.51e-05	0.000132	CcSEcCtD
Duloxetine—Decreased appetite—Doxorubicin—kidney cancer	6.43e-05	0.00013	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Doxorubicin—kidney cancer	6.39e-05	0.000129	CcSEcCtD
Duloxetine—Fatigue—Doxorubicin—kidney cancer	6.38e-05	0.000129	CcSEcCtD
Duloxetine—Constipation—Doxorubicin—kidney cancer	6.33e-05	0.000128	CcSEcCtD
Duloxetine—Pain—Doxorubicin—kidney cancer	6.33e-05	0.000128	CcSEcCtD
Duloxetine—Feeling abnormal—Doxorubicin—kidney cancer	6.1e-05	0.000123	CcSEcCtD
Duloxetine—Gastrointestinal pain—Doxorubicin—kidney cancer	6.05e-05	0.000122	CcSEcCtD
Duloxetine—Urticaria—Doxorubicin—kidney cancer	5.88e-05	0.000119	CcSEcCtD
Duloxetine—Body temperature increased—Doxorubicin—kidney cancer	5.85e-05	0.000118	CcSEcCtD
Duloxetine—Abdominal pain—Doxorubicin—kidney cancer	5.85e-05	0.000118	CcSEcCtD
Duloxetine—Hypersensitivity—Doxorubicin—kidney cancer	5.45e-05	0.00011	CcSEcCtD
Duloxetine—Asthenia—Doxorubicin—kidney cancer	5.31e-05	0.000107	CcSEcCtD
Duloxetine—Pruritus—Doxorubicin—kidney cancer	5.23e-05	0.000106	CcSEcCtD
Duloxetine—Diarrhoea—Doxorubicin—kidney cancer	5.06e-05	0.000102	CcSEcCtD
Duloxetine—Dizziness—Doxorubicin—kidney cancer	4.89e-05	9.89e-05	CcSEcCtD
Duloxetine—Vomiting—Doxorubicin—kidney cancer	4.7e-05	9.51e-05	CcSEcCtD
Duloxetine—Rash—Doxorubicin—kidney cancer	4.66e-05	9.43e-05	CcSEcCtD
Duloxetine—Dermatitis—Doxorubicin—kidney cancer	4.66e-05	9.42e-05	CcSEcCtD
Duloxetine—Headache—Doxorubicin—kidney cancer	4.63e-05	9.37e-05	CcSEcCtD
Duloxetine—Nausea—Doxorubicin—kidney cancer	4.39e-05	8.88e-05	CcSEcCtD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	3.06e-05	0.00053	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PDHB—kidney cancer	3.05e-05	0.000529	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—PIK3CA—kidney cancer	3.05e-05	0.000528	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—POMC—kidney cancer	3.04e-05	0.000527	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—RAF1—kidney cancer	3.03e-05	0.000524	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—RELA—kidney cancer	3.01e-05	0.000522	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—kidney cancer	3.01e-05	0.000522	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ERBB2—kidney cancer	2.99e-05	0.000519	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—ANXA1—kidney cancer	2.99e-05	0.000518	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CTNNA1—kidney cancer	2.99e-05	0.000518	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EIF4EBP1—kidney cancer	2.97e-05	0.000515	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HSPB1—kidney cancer	2.97e-05	0.000515	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MTOR—kidney cancer	2.96e-05	0.000512	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—MAPK1—kidney cancer	2.94e-05	0.00051	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GLIPR1—kidney cancer	2.94e-05	0.000509	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPAT—kidney cancer	2.94e-05	0.000509	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CCBL1—kidney cancer	2.87e-05	0.000497	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—kidney cancer	2.87e-05	0.000496	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	2.86e-05	0.000496	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP2—kidney cancer	2.86e-05	0.000495	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKAP13—kidney cancer	2.86e-05	0.000495	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—POMC—kidney cancer	2.86e-05	0.000495	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—PIK3CA—kidney cancer	2.78e-05	0.000481	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CDKN1B—kidney cancer	2.77e-05	0.00048	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ANXA1—kidney cancer	2.76e-05	0.000479	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PSMD7—kidney cancer	2.76e-05	0.000479	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TSC1—kidney cancer	2.76e-05	0.000479	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APRT—kidney cancer	2.73e-05	0.000473	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—FH—kidney cancer	2.73e-05	0.000473	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL2—kidney cancer	2.71e-05	0.00047	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	2.71e-05	0.000469	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FLT1—kidney cancer	2.68e-05	0.000464	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCND1—kidney cancer	2.65e-05	0.000458	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—JUN—kidney cancer	2.64e-05	0.000457	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CTNNB1—kidney cancer	2.62e-05	0.000454	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GRB7—kidney cancer	2.61e-05	0.000453	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—RAF1—kidney cancer	2.6e-05	0.000451	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.59e-05	0.000449	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GPC3—kidney cancer	2.57e-05	0.000445	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PTEN—kidney cancer	2.55e-05	0.000442	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—POMC—kidney cancer	2.52e-05	0.000437	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CA2—kidney cancer	2.5e-05	0.000432	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPAT—kidney cancer	2.49e-05	0.000431	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GLIPR1—kidney cancer	2.49e-05	0.000431	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	2.49e-05	0.000431	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—JUNB—kidney cancer	2.48e-05	0.00043	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PAK1—kidney cancer	2.48e-05	0.00043	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKAP13—kidney cancer	2.48e-05	0.00043	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP2—kidney cancer	2.48e-05	0.00043	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.46e-05	0.000425	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALAD—kidney cancer	2.43e-05	0.000421	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.43e-05	0.000421	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ITPR2—kidney cancer	2.43e-05	0.000421	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ST3GAL2—kidney cancer	2.37e-05	0.000411	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALDH1A1—kidney cancer	2.32e-05	0.000402	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APRT—kidney cancer	2.31e-05	0.000401	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—FH—kidney cancer	2.31e-05	0.000401	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—RAF1—kidney cancer	2.31e-05	0.0004	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VEGFA—kidney cancer	2.31e-05	0.0004	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—POMC—kidney cancer	2.29e-05	0.000397	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GRB7—kidney cancer	2.27e-05	0.000393	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.26e-05	0.000391	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PGK1—kidney cancer	2.23e-05	0.000385	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC5A3—kidney cancer	2.23e-05	0.000385	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CTNNA1—kidney cancer	2.2e-05	0.000381	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HSPB1—kidney cancer	2.19e-05	0.000379	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EIF4EBP1—kidney cancer	2.19e-05	0.000379	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LDHB—kidney cancer	2.18e-05	0.000378	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MAPK3—kidney cancer	2.18e-05	0.000378	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GPC3—kidney cancer	2.17e-05	0.000377	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MYC—kidney cancer	2.12e-05	0.000368	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CA2—kidney cancer	2.11e-05	0.000366	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ITPR2—kidney cancer	2.11e-05	0.000365	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MAPK1—kidney cancer	2.08e-05	0.00036	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALAD—kidney cancer	2.06e-05	0.000357	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TSC1—kidney cancer	2.04e-05	0.000353	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PSMD7—kidney cancer	2.04e-05	0.000353	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ANXA1—kidney cancer	2.04e-05	0.000353	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF2—kidney cancer	2.03e-05	0.000351	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN2B—kidney cancer	2.02e-05	0.00035	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ST3GAL2—kidney cancer	2.01e-05	0.000348	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FLT1—kidney cancer	1.97e-05	0.000341	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALDH1A1—kidney cancer	1.97e-05	0.000341	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF1R—kidney cancer	1.96e-05	0.00034	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—KRAS—kidney cancer	1.96e-05	0.00034	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CTNNA1—kidney cancer	1.91e-05	0.000331	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EIF4EBP1—kidney cancer	1.9e-05	0.000329	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HSPB1—kidney cancer	1.9e-05	0.000329	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CA9—kidney cancer	1.89e-05	0.000328	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—RAF1—kidney cancer	1.89e-05	0.000327	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PGK1—kidney cancer	1.89e-05	0.000327	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC5A3—kidney cancer	1.89e-05	0.000327	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—IL2—kidney cancer	1.87e-05	0.000323	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—POMC—kidney cancer	1.86e-05	0.000322	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LDHB—kidney cancer	1.85e-05	0.00032	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JUNB—kidney cancer	1.83e-05	0.000317	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PAK1—kidney cancer	1.83e-05	0.000317	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PIK3CA—kidney cancer	1.8e-05	0.000312	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TSC1—kidney cancer	1.77e-05	0.000306	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PSMD7—kidney cancer	1.77e-05	0.000306	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ANXA1—kidney cancer	1.77e-05	0.000306	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—kidney cancer	1.74e-05	0.000302	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FLT1—kidney cancer	1.71e-05	0.000297	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL2—kidney cancer	1.69e-05	0.000294	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—POMC—kidney cancer	1.69e-05	0.000292	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HIF1A—kidney cancer	1.61e-05	0.00028	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—POMC—kidney cancer	1.61e-05	0.00028	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TSC2—kidney cancer	1.61e-05	0.000279	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CRABP1—kidney cancer	1.61e-05	0.000279	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CA9—kidney cancer	1.6e-05	0.000278	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PAK1—kidney cancer	1.59e-05	0.000275	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JUNB—kidney cancer	1.59e-05	0.000275	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.57e-05	0.000271	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KDR—kidney cancer	1.54e-05	0.000268	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ITPR2—kidney cancer	1.5e-05	0.000259	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF2—kidney cancer	1.49e-05	0.000259	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN2B—kidney cancer	1.49e-05	0.000258	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—POMC—kidney cancer	1.47e-05	0.000254	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1R—kidney cancer	1.44e-05	0.00025	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APC—kidney cancer	1.42e-05	0.000246	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KIT—kidney cancer	1.42e-05	0.000246	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—RAF1—kidney cancer	1.39e-05	0.000241	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL2—kidney cancer	1.37e-05	0.000238	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ACHE—kidney cancer	1.36e-05	0.000236	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTT1—kidney cancer	1.36e-05	0.000236	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CRABP1—kidney cancer	1.36e-05	0.000236	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—MAPK3—kidney cancer	1.36e-05	0.000236	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—POMC—kidney cancer	1.35e-05	0.000235	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—BRAF—kidney cancer	1.34e-05	0.000232	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF2—kidney cancer	1.3e-05	0.000225	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—MAPK1—kidney cancer	1.3e-05	0.000225	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN2B—kidney cancer	1.29e-05	0.000224	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SCARB1—kidney cancer	1.29e-05	0.000224	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS1—kidney cancer	1.28e-05	0.000221	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ITPR2—kidney cancer	1.27e-05	0.000219	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1R—kidney cancer	1.25e-05	0.000217	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PSMD7—kidney cancer	1.25e-05	0.000217	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2—kidney cancer	1.25e-05	0.000216	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CA—kidney cancer	1.24e-05	0.000215	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—KRAS—kidney cancer	1.22e-05	0.000212	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—RAF1—kidney cancer	1.21e-05	0.000209	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2—kidney cancer	1.19e-05	0.000207	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HIF1A—kidney cancer	1.19e-05	0.000206	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—BCHE—kidney cancer	1.19e-05	0.000206	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TSC2—kidney cancer	1.19e-05	0.000205	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC5A5—kidney cancer	1.17e-05	0.000203	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.17e-05	0.000202	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ACHE—kidney cancer	1.16e-05	0.0002	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTT1—kidney cancer	1.16e-05	0.0002	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KDR—kidney cancer	1.14e-05	0.000197	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC2A1—kidney cancer	1.13e-05	0.000196	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CA—kidney cancer	1.13e-05	0.000195	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RAF1—kidney cancer	1.12e-05	0.000193	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RELA—kidney cancer	1.11e-05	0.000193	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ERBB2—kidney cancer	1.1e-05	0.000191	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SCARB1—kidney cancer	1.09e-05	0.000189	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MTOR—kidney cancer	1.09e-05	0.000189	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2—kidney cancer	1.08e-05	0.000188	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS1—kidney cancer	1.08e-05	0.000188	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PSMD7—kidney cancer	1.06e-05	0.000184	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APC—kidney cancer	1.05e-05	0.000181	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KIT—kidney cancer	1.05e-05	0.000181	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HIF1A—kidney cancer	1.03e-05	0.000179	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TSC2—kidney cancer	1.03e-05	0.000178	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1B—kidney cancer	1.02e-05	0.000177	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—BCHE—kidney cancer	1.01e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MAPK3—kidney cancer	1e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2—kidney cancer	1e-05	0.000173	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—POMC—kidney cancer	9.97e-06	0.000173	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC5A5—kidney cancer	9.94e-06	0.000172	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KDR—kidney cancer	9.88e-06	0.000171	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BRAF—kidney cancer	9.85e-06	0.000171	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCND1—kidney cancer	9.76e-06	0.000169	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—JUN—kidney cancer	9.74e-06	0.000169	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CTNNB1—kidney cancer	9.67e-06	0.000167	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC2A1—kidney cancer	9.6e-06	0.000166	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MAPK1—kidney cancer	9.55e-06	0.000165	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTP1—kidney cancer	9.45e-06	0.000164	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTEN—kidney cancer	9.42e-06	0.000163	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	9.32e-06	0.000161	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CA—kidney cancer	9.12e-06	0.000158	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APC—kidney cancer	9.1e-06	0.000158	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KIT—kidney cancer	9.1e-06	0.000158	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—KRAS—kidney cancer	9.02e-06	0.000156	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCB1—kidney cancer	8.95e-06	0.000155	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAPK3—kidney cancer	8.71e-06	0.000151	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTM1—kidney cancer	8.69e-06	0.00015	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—POMC—kidney cancer	8.66e-06	0.00015	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BRAF—kidney cancer	8.55e-06	0.000148	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—kidney cancer	8.51e-06	0.000147	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAPK1—kidney cancer	8.29e-06	0.000144	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CA—kidney cancer	8.28e-06	0.000144	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP1A1—kidney cancer	8.24e-06	0.000143	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RAF1—kidney cancer	8.22e-06	0.000142	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RELA—kidney cancer	8.19e-06	0.000142	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB2—kidney cancer	8.14e-06	0.000141	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	8.12e-06	0.000141	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK3—kidney cancer	8.05e-06	0.000139	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MTOR—kidney cancer	8.03e-06	0.000139	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTP1—kidney cancer	8.01e-06	0.000139	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CA—kidney cancer	7.92e-06	0.000137	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—KRAS—kidney cancer	7.83e-06	0.000136	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—kidney cancer	7.83e-06	0.000136	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK1—kidney cancer	7.66e-06	0.000133	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCB1—kidney cancer	7.58e-06	0.000131	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	7.53e-06	0.000131	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2—kidney cancer	7.37e-06	0.000128	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTM1—kidney cancer	7.36e-06	0.000127	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KRAS—kidney cancer	7.23e-06	0.000125	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	7.19e-06	0.000125	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCND1—kidney cancer	7.19e-06	0.000124	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JUN—kidney cancer	7.17e-06	0.000124	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RAF1—kidney cancer	7.14e-06	0.000124	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	7.12e-06	0.000123	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RELA—kidney cancer	7.11e-06	0.000123	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB2—kidney cancer	7.06e-06	0.000122	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP1A1—kidney cancer	6.98e-06	0.000121	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MTOR—kidney cancer	6.97e-06	0.000121	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTEN—kidney cancer	6.94e-06	0.00012	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CA—kidney cancer	6.65e-06	0.000115	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	6.54e-06	0.000113	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—kidney cancer	6.43e-06	0.000111	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2—kidney cancer	6.4e-06	0.000111	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—kidney cancer	6.27e-06	0.000109	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCND1—kidney cancer	6.24e-06	0.000108	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JUN—kidney cancer	6.23e-06	0.000108	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	6.18e-06	0.000107	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—POMC—kidney cancer	6.14e-06	0.000106	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTEN—kidney cancer	6.02e-06	0.000104	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK3—kidney cancer	5.93e-06	0.000103	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—kidney cancer	5.77e-06	9.99e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.73e-06	9.93e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK1—kidney cancer	5.64e-06	9.77e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—kidney cancer	5.44e-06	9.43e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KRAS—kidney cancer	5.33e-06	9.23e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—POMC—kidney cancer	5.2e-06	9.01e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK3—kidney cancer	5.15e-06	8.92e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—kidney cancer	5.01e-06	8.67e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK1—kidney cancer	4.9e-06	8.48e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—kidney cancer	4.9e-06	8.48e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	4.89e-06	8.48e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—kidney cancer	4.73e-06	8.2e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KRAS—kidney cancer	4.63e-06	8.01e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTEN—kidney cancer	4.27e-06	7.4e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	4.25e-06	7.36e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—kidney cancer	4.15e-06	7.19e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—kidney cancer	4.11e-06	7.12e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTEN—kidney cancer	3.62e-06	6.27e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CA—kidney cancer	3.01e-06	5.22e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CA—kidney cancer	2.55e-06	4.42e-05	CbGpPWpGaD
